NASDAQ:IRIX - IRIDEX Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$8.07 +0.26 (+3.33 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$7.81
Today's Range$7.77 - $8.07
52-Week Range$4.28 - $10.98
Volume12,900 shs
Average Volume20,007 shs
Market Capitalization$93.31 million
P/E Ratio-7.27
Dividend YieldN/A
Beta1.51
IRIDEX logoIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
SymbolNASDAQ:IRIX
CUSIPN/A
Phone650-940-4700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.28
Quick Ratio2.38

Price-To-Earnings

Trailing P/E Ratio-7.27
Forward P/E Ratio-7.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$41.59 million
Price / Sales2.26
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book3.06

Profitability

EPS (Most Recent Fiscal Year)($1.11)
Net Income$-12,860,000.00
Net Margins-36.98%
Return on Equity-48.89%
Return on Assets-37.08%

Miscellaneous

Employees116
Outstanding Shares11,660,000
Market Cap$93.31 million

IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) posted its earnings results on Thursday, August, 2nd. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.04. The medical equipment provider had revenue of $10.30 million for the quarter, compared to analyst estimates of $9.21 million. IRIDEX had a negative return on equity of 48.89% and a negative net margin of 36.98%. View IRIDEX's Earnings History.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for IRIDEX.

What price target have analysts set for IRIX?

1 Wall Street analysts have issued 1 year price targets for IRIDEX's shares. Their predictions range from $13.00 to $13.00. On average, they expect IRIDEX's stock price to reach $13.00 in the next year. This suggests a possible upside of 61.1% from the stock's current price. View Analyst Price Targets for IRIDEX.

What is the consensus analysts' recommendation for IRIDEX?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.

Who are some of IRIDEX's key competitors?

Who are IRIDEX's key executives?

IRIDEX's management team includes the folowing people:
  • Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 69)
  • Mr. Atabak Mokari, CFO & VP of Corp. Devel. (Age 41)
  • Dr. George R. Marcellino, VP of Clinical Affairs (Age 69)
  • Ms. Leigh Salvo, Head of Investor Relations
  • Mr. Timothy D. Buckley, VP of Global Marketing & Bus. Devel. (Age 43)

Has IRIDEX been receiving favorable news coverage?

Media stories about IRIX stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IRIDEX earned a news and rumor sentiment score of 0.22 on Accern's scale. They also gave press coverage about the medical equipment provider an impact score of 46.08 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for IRIDEX.

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.76%), First Light Asset Management LLC (1.70%), Eidelman Virant Capital (0.96%), Perkins Capital Management Inc. (0.62%) and BlackRock Inc. (0.31%). Company insiders that own IRIDEX stock include George R Marcellino, Romeo R Dizon, Ruediger Naumann-Etienne and William M Moore. View Institutional Ownership Trends for IRIDEX.

Which institutional investors are selling IRIDEX stock?

IRIX stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC. View Insider Buying and Selling for IRIDEX.

Which institutional investors are buying IRIDEX stock?

IRIX stock was bought by a variety of institutional investors in the last quarter, including Eidelman Virant Capital, Renaissance Technologies LLC, Perkins Capital Management Inc. and BlackRock Inc.. View Insider Buying and Selling for IRIDEX.

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $8.07.

How big of a company is IRIDEX?

IRIDEX has a market capitalization of $93.31 million and generates $41.59 million in revenue each year. The medical equipment provider earns $-12,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. IRIDEX employs 116 workers across the globe.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]


MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe IRIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Featured Article: Google Finance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.